

Dear Editor,

I would like to thank all three reviewers for taking the time to provide such expert and constructive critical appraisal. I have addressed each of the points (see below) and made a reference to the specific line in the new text where these changes can be found.

I feel like these amendments have made for a paper of higher quality and I hope this will satisfy the reviewers.

Yours sincerely,

Dr.Patrick McCrossan

Reviewer #2:
Scientific Quality: Grade B (Very good)
Language Quality: Grade B (Minor language polishing)
Conclusion: Accept (General priority)

Specific Comments to Authors: Since omalizumab is considered a biologic drug it would be important to consider the possible adverse drug reactions after treatment. Also, including and discussing the guidance recommendations for prescribing omalizumab would add valuable information to readers.

Many thanks for the feedback. We have since included the side effect profile of Omalizumab (see lines 117-124) and we have also included the current recommendations for prescribing Omalizuamb (see lines 58-62 and table 2) and dosing recommendations (see lines 63-72).